Metabolic effects of a new hypolipidemic agent, ciprofibrate.

Abstract

Ciprofibrate, a new orally effective hypolipidemic agent like clofibrate, suppressed tyloxapol-induced hypercholesterolemia in rats. Ciprofibrate at 10 mg/kg was effective. Clofibrate required a dosage of 180 mg/kg to suppress the tyloxapol effect. Norepinephrine-induced free fatty acid release was inhibited by clofibrate in rats in accordance with earlier findings. Ciprofibrate and lifibrate differed from clofibrate in that, at hypocholesterolemically effective doses, neither inhibited the hormone sensitive lipase in vivo.

• Authors: A Arnold, M P McAuliff, A L Beyler
• Journal: Journal of pharmaceutical sciences (J Pharm Sci) Vol. 68 Issue 12 Pg. 1557-8 (Dec 1979) ISSN: 0022-3549 [Print] United States
• PMID: 529054 (Publication Type: Journal Article)

Chemical References

• Fatty Acids, Nonesterified
• Fibric Acids
• Hypolipidemic Agents
• Polyethylene Glycols
• Clofibric Acid
• Cholesterol
• Lipase
• ciprofibrate
• Clofibrate
• Norepinephrine

Topics

• Animals
• Cholesterol (blood)
• Clofibrate (analogs & derivatives)
• Clofibric Acid (analogs & derivatives, pharmacology)
• Fatty Acids, Nonesterified (blood)
• Fibric Acids
• Hypolipidemic Agents (pharmacology)
• Lipase (antagonists & inhibitors)
• Norepinephrine (pharmacology)
• Polyethylene Glycols (pharmacology)
• Rats